Expression of the VEP13 antigen (CD16) on native human alveolar macrophages and cultured blood monocytes.
Human alveolar macrophages (AM phi) from thirteen patients, who were suffering from various lung diseases were harvested by bronchoalveolar lavage. Peripheral blood monocytes from eight healthy donors were isolated by Ficoll-Hypaque gradient centrifugation and adherence to plastic surface. To detect the VEP13 antigen (CD16) on these cells, a rosette assay employing ox erythrocytes coated by the CrCl3 method with purified VEP13 monoclonal antibody (Eo-VEP13) was used. A mean of 31.3% of freshly isolated AM phi and 3.9% of blood monocytes formed Eo-VEP13 rosettes. Monocytes cultured for 3 or 6 days in the presence of a supernatant from mouse L929 cells, which had been shown previously to improve long-term viability of human monocytes in culture, showed 12.5% and 25.3% Eo-VEP13 rosettes, respectively. No significant increase in VEP13 antigen expression was noted by culturing monocytes without L929 cell supernatant. The factor in L929 supernatant that induces VEP13 antigen expression has not been identified. Tunicamycin at 10 micrograms/ml inhibited significantly VEP13 antigen expression on monocytes. In contrast, IgG rosette formation was not reduced by tunicamycin. Our data show that subpopulations of native human AM phi and peripheral blood monocytes cultured in presence of a supernatant of L929 fibroblasts containing mainly murine CSF may express the CD16 antigen, which is normally found on large granular lymphocytes (LGL). Suppression by tunicamycin indicates that Fc receptor glycosylation takes place during a later differentiation step of mononuclear phagocytes.
Baumgartner
I
I
Institute of General and Experimental Pathology, University of Vienna, Austria.
Scheiner
O
O
Holzinger
C
C
Boltz-Nitulescu
G
G
Klech
H
H
Lassmann
H
H
Rumpold
H
H
Förster
O
O
Kraft
D
D
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation / Q000302:isolation & purification*; D002478:Cells, Cultured; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008264:Macrophages / Q000145:classification / Q000276:immunology*; D008297:Male; D009000:Monocytes / Q000145:classification / Q000187:drug effects / Q000276:immunology*; D011650:Pulmonary Alveoli / Q000276:immunology*; D011961:Receptors, Fc / Q000302:isolation & purification*; D017452:Receptors, IgG; D012397:Rosette Formation; D014415:Tunicamycin / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D000943:Antigens, Differentiation; D011961:Receptors, Fc; D017452:Receptors, IgG; D014415:Tunicamycin